Trial · NCT03077451
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants | Treatment (Nelfinavir Mesylate) | 32 | 95% Confidence Interval 14.9 to 53.5 | percentage of overall response patients | |
| Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Negative Participants | Treatment (Nelfinavir Mesylate) | 16.7 | 95% Confidence Interval 0.4 to 64.1 | percentage of overall response patients | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Anemia | 7 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Blood and Lymphatic System Disorder | 2 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Abdominal Pain | 3 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Constipation | 2 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Diarrhea | 42 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Nausea | 7 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Vomiting | 2 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Edema Limbs | 6 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Fever | 3 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | General Disorders and Administration Site Conditions | 7 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Pain | 6 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Herpes Simplex reactivation | 3 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Infections and Infestations | 6 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Injury, Poisoning and Procedural Complications | 4 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Neutrophil Count Decreased | 5 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | White Blood Cell Decreased | 3 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Anorexia | 2 | Number of adverse events | |
| Frequency and Severity of Adverse Events in HIV-positive Participants as Assessed by CTCAE v4.0 | High Dose of Nelfinavir in the Treatment of KS in Participant Who Are HIV-positive | Hyperglycemia | 3 | Number of adverse events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03077451/results